[{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Neurology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Neurology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Assia Chemical Industries Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Assia Chemical Industries Ltd"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Colesevelam Hydrochloride","moa":"Bile acid","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Colesevelam Hydrochloride","moa":"Bile acid","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Colesevelam Hydrochloride","moa":"Bile acid","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"Comet Therapeutics","sponsor":"VectivBio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"VB-1197","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Comet Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Comet Therapeutics \/ VectivBio","highestDevelopmentStatusID":"4","companyTruncated":"Comet Therapeutics \/ VectivBio"},{"orgOrder":0,"company":"VectivBio","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ SVB Securities"},{"orgOrder":0,"company":"VectivBio","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Financing","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Surveyor Capital","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Surveyor Capital"},{"orgOrder":0,"company":"VectivBio","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"VectivBio","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"VectivBio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Jefferies"},{"orgOrder":0,"company":"VectivBio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Jefferies"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IW-3300","moa":"Guanylate cyclase C","graph1":"Neurology","graph2":"Phase I","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Ironwood Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : FE-203799 (apraglutide) is a once-weekly , a next-generation, long-acting glucagon-like peptide-2 (GLP-2) analog. It is being evaluated for the treatment of short bowel syndrome.

                          Product Name : FE-203799

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          April 14, 2025

                          Lead Product(s) : Apraglutide

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : FE-203799 (apraglutide) is a once-weekly , a next-generation, long-acting glucagon-like peptide-2 (GLP-2) analog. It is being evaluated for the treatment of short bowel syndrome.

                          Product Name : FE-203799

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          January 29, 2025

                          Lead Product(s) : Apraglutide

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : FE-203799 (apraglutide) is a long-acting GLP-2 analog under evaluation for steroid-refractory gastrointestinal acute graft-versus-host disease.

                          Product Name : FE203799

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          March 28, 2024

                          Lead Product(s) : Apraglutide

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : FE-203799 (apraglutide) is an investigational, next-generation, long-acting synthetic GLP-2 analog. It is being evaluated for the treatment of short bowel syndrome with intestinal failure.

                          Product Name : FE203799

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          February 29, 2024

                          Lead Product(s) : Apraglutide

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).

                          Product Name : FE203799

                          Product Type : Peptide

                          Upfront Cash : $1,000.0 million

                          December 12, 2023

                          Lead Product(s) : Apraglutide

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Ironwood Pharmaceuticals

                          Deal Size : $1,000.0 million

                          Deal Type : Acquisition

                          blank

                          06

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Linzess (linaclotide) is the first and only FDA-approved prescription therapy for irritable bowel syndrome with constipation and chronic idiopathic constipation (CIC) in adults and functional constipation (FC) in children and adolescents 6 to 17 years of...

                          Product Name : Linzess

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 06, 2023

                          Lead Product(s) : Linaclotide

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : AbbVie Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).

                          Product Name : FE203799

                          Product Type : Peptide

                          Upfront Cash : $1,000.0 million

                          May 22, 2023

                          Lead Product(s) : Apraglutide

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Ironwood Pharmaceuticals

                          Deal Size : $1,000.0 million

                          Deal Type : Acquisition

                          blank

                          08

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Apraglutide is a novel long-acting glucagon-like peptide-2 analog designed for to increase fluid and nutrient absorption by the remnant intestine of patients who have short bowel syndrome with intestinal insufficiency or intestinal failure.

                          Product Name : FE203799

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          March 13, 2023

                          Lead Product(s) : Apraglutide

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Asahi Kasei Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Linzess (linaclotide) is a guanylate cyclase-C (GC-C) agonist. Activation of GC-C results in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine. It is being developed for IB...

                          Product Name : Linzess

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          February 13, 2023

                          Lead Product(s) : Linaclotide

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : VectivBio intends to use the net proceeds from the offering, (i) clinical development and pre-commercialization activities for its lead product FE203799 (apraglutide) and (ii) general corporate purposes, including general and administrative expenses and ...

                          Product Name : FE203799

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          October 18, 2022

                          Lead Product(s) : Apraglutide

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Jefferies

                          Deal Size : $125.0 million

                          Deal Type : Public Offering

                          blank